Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Brookside Capital and Immune Design Corp. (IMDZ)

Immune Design Corp. (NASDAQ:IMDZ): Bain Capital’s Brookside Capital filed an amended 13D.

You can check out Brookside Capital’s latest holdings and filings here.

Please follow Brookside Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Brookside Capital or update its stock holdings.

Bain Capital
Bain Capital
Brookside Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Bain Capital Public Equity Management 1,299,013 0 1,299,013 0 1,299,013 5.07%
Brookside Capital Investors II 1,299,013 0 1,299,013 0 1,299,013 5.07%
Brookside Capital Trading Fund 1,299,013 0 1,299,013 0 1,299,013 5.07%
Bain Capital
Bain Capital
Brookside Capital

Page 1 of 7 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ________)*
Immune Design Corp. (Name of Issuer)
Common Stock
(Title of Class of Securities)
45252L103 (CUSIP Number)
September 29, 2017
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:
? Rule 13d-1(b)
? Rule 13d-1(c)
? Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures
provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45252L103

13G

Page 2 of 8

Follow Immune Design Corp. (NASDAQ:IMDZ)
Trade (NASDAQ:IMDZ) Now!

Page 2 of 7 – SEC Filing

1.

NAMES OF REPORTING PERSONS

Bain Capital Public Equity Management, LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ?
(b) ?

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

DelawareNUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

1,299,013

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

1,299,013

8.

SHARED DISPOSITIVE POWER

09.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,299,013

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ?11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.07%

12.

TYPE OF REPORTING PERSON (see instructions)

PNCUSIP No. 45252L103

13G

Page 3 of 81.

NAMES OF REPORTING PERSONS

Brookside Capital Investors II, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ?
(b) ?

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

DelawareNUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

1,299,013

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

1,299,013

8.

SHARED DISPOSITIVE POWER

0

Follow Immune Design Corp. (NASDAQ:IMDZ)
Trade (NASDAQ:IMDZ) Now!

Page 3 of 7 – SEC Filing

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.07%

12.

TYPE OF REPORTING PERSON (see instructions)

PNCUSIP No. 45252L103

13G

Page 4 of 8 Pages1.

NAMES OF REPORTING PERSONS

Brookside Capital Trading Fund, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ?
(b) ?

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

DelawareNUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

1,299,013

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

1,299,013

8.

SHARED DISPOSITIVE POWER

09.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,299,013

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ?11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.07%

12.

TYPE OF REPORTING PERSON (see instructions)

PNCUSIP No. 45252L103

13G

Page 5 of 8Item 1.

(a)
Name of Issuer
The name of the issuer to which this filing on Schedule 13G
relates is Immune Design Corp. (the “Company”)

Follow Immune Design Corp. (NASDAQ:IMDZ)
Trade (NASDAQ:IMDZ) Now!

Page 4 of 7 – SEC Filing

(b)
Address of the Principal Office or, if none, residence
The principal business address of each of the Trading Fund, Brookside
Investors II and BCPE Management is c/o Bain Capital Public Equity, LP,
200 Clarendon Street, Boston, MA 02116.(c)
Citizenship
Each of the Trading Fund, Brookside Investors II and BCPE Management
is organized under the laws of the State of
Delaware.(d)
Title of Class of Securities
The class of equity securities of the Company to which this filing on
Schedule 13G relates is Common Stock
(“Common Stock”).(e)
CUSIP Number
The CUSIP number of the Company’s Common Stock is 45252L103.

Item 3. If this statement is filed pursuant to 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:

(a)
?
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).(b)
?
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).(c)
?
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).(d)
?
Investment company registered under section 8 of the Investment Company
Act of 1940 (15 U.S.C. 80a-8).

Follow Immune Design Corp. (NASDAQ:IMDZ)
Trade (NASDAQ:IMDZ) Now!

Page 5 of 7 – SEC Filing

(f)
?
An employee benefit plan or endowment fund in accordance with
240.13d-1(b)(1)(ii)(F);(g)
?
A parent holding company or control person in accordance with
240.13d-1(b)(1)(ii)(G);(h)
?
A savings associations as defined in Section 3(b) of the Federal Deposit
Insurance Act (12 U.S.C. 1813);(i)
?
A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act
of 1940 (15 U.S.C. 80a-3);(j)
?
Group, in accordance with 240.13d-1(b)(1)(ii)(J).[x] If this statement is filed pursuant to 240.13d-1(c), check this box.
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer
identified in Item 1.(a)

Amount beneficially owned: 1,299,013.(b)

Percent of class: 5.07% based upon 25,619,732 shares
of Common Stock outstanding.(c)

Number of shares as to which the person has: 1,299,013.(i)
Sole power to vote or to direct the vote: 1,299,013.(ii)
Shared power to vote or to direct the vote: 0.

Follow Immune Design Corp. (NASDAQ:IMDZ)
Trade (NASDAQ:IMDZ) Now!

Page 6 of 7 – SEC Filing

(iv)
Shared power to dispose or to direct the disposition of: 0.Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Holding Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that
purpose or effect.CUSIP No. 45252L103

13G

Page 7 of 8After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement
is true, complete and correct.
Dated: October 6, 2017

BAIN CAPITAL PUBLIC EQUITY MANAGEMENT, LLC

By:
Name: Joshua Ross
Title: Managing Director

BROOKSIDE CAPITAL INVESTORS II, L.P.
By: Bain Capital Public Equity Management, LLC,
its general partner
By:
Name: Joshua Ross
Title: Managing Director

BROOKSIDE CAPITAL TRADING FUND, L.P.
By: Brookside Capital Investors II, L.P.,
its general partner
By: Bain Capital Public Equity Management, LLC,
its general partner

By:
Name: Joshua Ross
Title: Managing Director

Follow Immune Design Corp. (NASDAQ:IMDZ)
Trade (NASDAQ:IMDZ) Now!

Page 7 of 7 – SEC Filing

The percentage of Common Stock reported owned by the Reporting Persons
is based upon 25,619,732 shares of Common Stock outstanding as reported
in the Issuer’s Quarterly Report on Form 10-Q dated June 30, 2017.
The percentage of Common Stock reported owned by the Reporting Persons
is based upon 25,619,732 shares of Common Stock outstanding as reported
in the Issuer’s Quarterly Report on Form 10-Q dated June 30, 2017. The
percentage of Common Stock reported owned by the Reporting Persons is
based upon 25,619,732 shares of Common Stock outstanding as reported
in the Issuer’s Quarterly Report on Form 10-Q dated June 30, 2017.48220740_1
48220740_1
48220740_1
48220740_1
Follow Immune Design Corp. (NASDAQ:IMDZ)
Trade (NASDAQ:IMDZ) Now!